Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2014', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Metastatic Hepatocellular Carcinoma (HCC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Hepatocellular Carcinoma (HCC) Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 8
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 9
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 10
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 12
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 15
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 16
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
AstraZeneca PLC 18
MedImmune, LLC 19
Novartis AG 20
Onyx Pharmaceuticals, Inc. 21
Active Biotech AB 22
Hutchison MediPharma Limited 23
OncoMed Pharmaceuticals, Inc. 24
Mirna Therapeutics, Inc. 25
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
codrituzumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tasquinimod - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cell Therapy for Hepatocellular Carcinoma - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
dusigitumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
oprozomib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AZD-9150 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HMPL-012 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
erismodegib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MRX-34 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ipafricept - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Cell Therapy for Metastatic Hepatocellular Carcinoma - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
UPO-901 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
OSU-2S - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates 57
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 69
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 70
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 71
Featured News & Press Releases 71
May 13, 2014: Provectus Biopharmaceuticals: Short-Term Catalysts and Positive Trial Results Could Help Shares 71
Apr 24, 2014: Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox in Primary Liver Cancer Presented at ECIO 2014 71
Mar 27, 2014: Five Prime Therapeutics To Present Data On FP-1039 At 2014 American Association For Cancer Research Meeting 72
Dec 13, 2013: Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer 72
Oct 09, 2013: Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study 73
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 73
Oct 02, 2013: MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer 75
Oct 01, 2013: U.S. FDA Grants Orphan Drug Designation to Delcath Systems for Use of Melphalan Hydrochloride in HCC 75
Sep 30, 2013: 4SC presents summary of biomarker and patient subgroup analysis of prognostic factors for survival in advanced HCC 76
Sep 13, 2013: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer 78
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2014 8
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 17
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca PLC., H2 2014 18
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MedImmune, LLC., H2 2014 19
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2014 20
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 21
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Active Biotech AB, H2 2014 22
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Hutchison MediPharma Limited, H2 2014 23
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 24
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H2 2014 57
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2014 69
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2014 70